Author
others
View
3
Download
0
Embed Size (px)
Drugs affecting Blood
Blood Clotting
• Blood clots are also called thrombi
• Develop from abnormalities with:
– Blood coagulation
– Blood flow
– Platelet adhesiveness
– Vessel walls
Blood Clotting
• Anticoagulants
– Prevent clot formation by inhibiting clotting factors
• Antiplatelets
– Reduce risk of clot formation by inhibiting platelet aggregation
• Fibrinolytics
– Dissolve clots already formed
Clotting Cascade
Clotting Cascade
• If any factor in the cascade is missing,
blood will not clot (hemophilia)
Venous Thrombi
• Usually form in areas of slow blood flow,
surgical or vein injuries, large venous
sinuses, or pockets formed by valves in
deep veins
• If the clot breaks off, it can travel to the
lung causing pulmonary embolism (PE)
DVT: Deep Vein Thrombosis
• Deep vein thrombosis above the knee is the
most serious and may be fatal
Risk Factors for DVT
• Age over 40
• Bed rest over 4 days
• Estrogen combined
with nicotine
• High dose estrogen
therapy
• Major illness
• Obesity
• Pregnancy
• Previous DVT
• Surgery
• Trauma
• Varicose veins
Laboratory Testing
• Certain lab tests must be done on patients
who are on anticoagulant therapy
Laboratory Testing
• Partial thromboplastin time (PTT) –
affected by heparin
• Prothrombin Time (PT) – affected by
warfarin
• International Normalized Ration (INR)
• Hematocrit
Anticoagulant Agents
• argatroban
• bivalirudin (Angiomax)
• fondaparinux (Arixtra)
• Heparin (protamine sulphate is antagonist)
• lepirudin (Refludan)
• warfarin (Coumadin) (Vit K ,phytonadione is antidot)
Drug
List
Anticoagulant Agents
Low-Molecular-Weight Heparins:
• dalteparin (Fragmin)
• enoxaparin (Lovenox)
• tinzaparin (Innohep)
Drug
List
heparin
• Inhibits thrombin formation preventing clots
from forming
• Only anticoagulant that does not cross the
placenta
• Given for prophylaxis of DVT in
postoperative, bedridden, obese patients,
and others
warfarin (Coumadin)
• Prevents production of vitamin
K-dependent clotting factors
• Prevents future clots with no effect on
existing clots
• Should not be taken with ASA or NSAIDs
Figure 20.14 Heparin- and low-molecular-weight heparin
(LMWH)–mediated inactivation of thrombin or
Factor Xa
Antiplatelet Agents
• aspirin
• clopidogrel (Plavix)
• ticlopidine (Ticlid)
Drug
List
Figure 20.4 Activation and
aggregation of platelets. GP
= glycoprotein.
Figure 20.5 Aspirin irreversibly
inhibits platelet cyclooxygenase-
1.
Figure 20.6 Acetylation of
cyclooxygenase-1 by aspirin.
Figure 20.7 Mechanism of action
of ticlopidine and clopidogrel. GP
= glycoprotein
clopidogrel (Plavix)
• Blocks ADP (adenosine diphosphate)
receptors and prevents platelet adhesion and
aggregation
• Used to prevent MI and stroke
• Major side effect is bleeding
Antiplatelet Agents
Glycoprotein Antagonists:
• abciximab (ReoPro)
• eptifibatide (Integrilin)
• tirofiban (Aggrastat)
Drug
List
Figure 20.8 Mechanism of
action of glycoprotein (GP)
IIb/IIIa–receptor blockers.
Figure 20.10 Formation of fibrin
clot.
Fibrinolytic Agents
• alteplase (Activase)
• reteplase (Retavase)
• streptokinase (Streptase)
• tenecteplase (TNKase)
• urokinase (Abbokinase)
Drug
List
Figure 20.21 Activation of plasminogen by fibrinolytic agents.
Stroke
• The brain is the most oxygen-rich organ
• If cerebral circulation is stopped, the brain
runs out of oxygen within 10 seconds, tissue
dies and does not regenerate
• A stroke is an interruption of oxygen supply
Types of Strokes
• Ischemic Stroke
• Cerebral Hemorrhage
Types of Strokes
• Ischemic Stroke
– Results from obstruction of blood flow due to a
thrombus or emboli lodging in the blood vessel
• Cerebral Hemorrhage
Types of Strokes
• Ischemic Stroke
• Cerebral Hemorrhage
– Involves primary rupture of a blood vessel
– Signs: sudden severe headache, stiff neck,
stupor, or a combination of these
– Effects are long-lasting and irreversible
Stroke Risk Factors
• Modifiable:
– Cigarette smoking
– Coronary artery
disease
– Diabetes
– Excessive alcohol
intake
– Hyperlipidemia
– Hypertension
– Obesity
– Physical inactivity
Stroke Risk Factors
• Non Modifiable
– Age
– Gender
– Genetic predisposition
– Prior stroke
– Race
Stroke Management
• Emphasis is on prevention
– Antiplatelet therapy
Stroke Management
• Emphasis is on prevention
– Antiplatelet therapy
– Anticoagulant therapy
Stroke Management
• Emphasis is on prevention
– Antiplatelet therapy
– Anticoagulant therapy
– Fibrinolytic intervention
Stroke Management
• Emphasis is on prevention
– Antiplatelet therapy
– Anticoagulant therapy
– Fibrinolytic intervention
– Cerebrovascular surgery
Stroke Management
• Emphasis is on prevention
– Antiplatelet therapy
– Anticoagulant therapy
– Fibrinolytic intervention
– Cerebrovascular surgery
– Nonpharmacologic therapy
Stroke Management
• Emphasis is on prevention
– Antiplatelet therapy
– Anticoagulant therapy
– Fibrinolytic intervention
– Cerebrovascular surgery
– Nonpharmacologic therapy
– Poststroke management
Stroke Management
• Emphasis is on prevention
– Antiplatelet therapy
– Anticoagulant therapy
– Fibrinolytic intervention
– Cerebrovascular surgery
– Nonpharmacologic therapy
– Poststroke management
• It is imperative to know the cause of the stroke to
determine treatment
Antiplatelet Agents
• Prevent platelet activation and formation of
platelet plug
– Can interfere with platelet aggregation induced
by ADP (adenosine diphosphate) or
– Interfere with synthesis of thromboxane
Anticoagulant Agents
• Interfere with the synthesis and activation
of the blood’s coagulation factors
• May prevent existing clots from expanding
• Does not reduce existing clots
Fibrinolytic Agents
• Dissolve existing emboli or thrombi
• Indications:
– DVT
– Acute peripheral occlusion
– Acute MI with embolization
– PE
– Coronary embolus
Agents for TIAs and
Stroke Prevention
• aspirin
• aspirin-dipyridamole (Aggrenox)
• clopidogrel (Plavix)
• dipyridamole (Persantine)
• pentoxifylline (Trental)
• ticlopidine (Ticlid)
Drug
List